Ruzivo rwezvekurapa rweRD13-02 rwekurapa varwere veR/R T-ALL/LBL mumuromo

RD13-02 chigadzirwa chemasero eCAR-T chinoshandiswa nevanhu vose chinotarisa CD7 inobva kune vanopa vane hutano, uye chakagadzirirwa kurapa recurly kana refractory T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL). Yakagadziriswa majini kudzivirira fratricide, graft-versus-host disease (GvHD), uye host-versus-graft rejection (HvG) ukuwo ichivandudza anti-bumor activity. RD13-02 inogona kugadzirwa muboka rimwe chete revanhu vakawanda, zvichiita kuti pave nekukwanisa "kwenguva pfupi" kune varwere vanoda CAR-T cell therapy.

Musi wa7 Mbudzi, 2024, Bioheng Therapeutics yakazivisa kuti ichaburitsa ruzivo rwekiriniki rwePase I rwechigadzirwa chayo cheCAR-T cell RD13-02, ichinanga CD7 yekurapa varwere vane relaxation/refractory(R/R) T-ALL/LBL, muhurukuro yemuromo paMusangano weGore we66th American Society of Hematology (ASH). Musangano uyu uchaitwa kubva musi wa7-10 Zvita, 2024, muSan Diego, USA.

Mhedzisiro: Kubva musi wa1 Nyamavhuvhu, 2024, vanhu gumi nevasere vakakodzera vane R/R T-ALL/LBL vakanyoreswa (13 ALL, 5 LBL), vane makore akaenzana nemakore 33.5 (kubva pa11 kusvika 67). Pakati pemitsetse yekurapa yaive miviri (kubva pa1 kusvika 5), ​​uye vana vana vaive neallo-HSCT vasati vanyoreswa. Chikamu chepakati cheBM blasts chaive 71% (kubva pa6% kusvika 90%) pakati pe18, ne9 (6 ALL, 3 LBL) vachiratidza kubatanidzwa kunze kwemedullary. Hapana chiitiko chedosi-limiting toxicity (DLT) kana neurotoxicity chakaonekwa pamatanho ese edosi, paine nyaya imwe chete yeGr1 GvHD yakaitika. Cytokine release syndrome (CRS) yaigoneka uye vazhinji vacho vaive vakapfava (Gr1, n=10; Gr2, n=5; Gr3, n=3). Kutapukirwa kwemhando ipi neipi kwakaitika muzvikamu gumi nezvitatu (72%) (≥Gr3 muzvikamu zviviri [11%]). Nekuda kwekuitika kweGr3 CRS muchikamu chimwe nechimwe kubva kumazinga eDL2 neDL3, vaongorori vakaisa DL1 semushonga wekuwedzera vachinyanya kutarisisa kuchengetedzeka uye kushanda zvakanaka. Munguva yekuwedzera kwemushonga, pt imwe chete yakafa nechirwere chetumor lysis syndrome paZuva rechi20 mushure mekuiswa mushonga.

Pakuongororwa kwekutanga kwemazuva makumi maviri nemasere mushure mekuiswa, 14 kubva pa17 pts dzakaongororwa dzakawana CR/CRi. Nepo pakasvika mwedzi wechipiri mushure mekuiswa, mamwe pt maviri akasvika CR/CRi, neCR/CRi rate ye94% (16/17). Pakati pepts dzine CR/CRi, 100% yakawana minimal residual disease (MRD) negative status kuburikidza ne flow cytometry analysis. Avhareji yeCmax yeCAR-T cells muropa re peripheral yaive 1,863,601 copies/μg genomic DNA (range, 275,044 kusvika 3,763,587) ne qPCR, uye nguva yakareba kupfuura mazuva makumi mapfumbamwe.

Mhedziso: RD13-02, chigadzirwa cheCAR-T chinoshandiswa nevanhu vose, chakaratidza kuchengetedzeka kwakanaka uye kushanda zvakanaka mukurapa R/R CD7 T-ALL/LBL. Zvinonyanya kukosha ndekuti, 100% yeCR/CRi pts yakawana MRD-negative, zvichipa mikana yakawanda yekurapa nekukurumidza.

Parizvino, kune mimwe miedzo yakawanda yeCAR-T muChina, uye vari kutsvaga varwere. Kuti muwane mazano pamusoro pemishonga mitsva netekinoroji, munogona kubata Beijing South Region Oncology Hospital International Department.

Nhamba yefoni: 4008803716

Email：myimmnet@163.com

Mareferensi

1.https://www.bioheng.com/News_Details/26.html

2.https://ash.confex.com/ash/2024/webprogram/Paper207322.html

3.http://myimm.net/mianyizhiliao/2035.html